# Safety, Tolerability, and Immunogenicity of One Dose of NDV 3A Vaccine in People With STAT3-Mutated Hyper-IgE Syndrome

> **NCT02996448** · PHASE2 · TERMINATED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 3 (actual)

## Conditions studied

- Autosomal-dominant Hyper-IgE Syndrome

## Interventions

- **DRUG:** NDV-3A

## Key facts

- **NCT ID:** NCT02996448
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-11-17
- **Primary completion:** 2018-07-22
- **Final completion:** 2018-10-09
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Safety concerns led to early termination.
- **Last updated:** 2020-06-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02996448

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02996448, "Safety, Tolerability, and Immunogenicity of One Dose of NDV 3A Vaccine in People With STAT3-Mutated Hyper-IgE Syndrome". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02996448. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*